Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
about
A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic InflammationVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationChitinase-3-like-1/YKL-40 as marker of circulating tumor cellsRole of tumor associated macrophages in tumor angiogenesis and lymphangiogenesisUnveiling YKL-40, from Serum Marker to Target Therapy in GlioblastomaInhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involutionSimulating tumor microenvironment: changes in protein expression in an in vitro co-culture system.Increased plasma YKL-40/chitinase-3-like-protein-1 is associated with endothelial dysfunction in obstructive sleep apnea.Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival.Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cellsCorrelation of chitinase 3-like 1 single nucleotide polymorphisms and haplotypes with uterine cervical cancer in Taiwanese women.High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancerThe NF-κB RelB protein is an oncogenic driver of mesenchymal gliomaExpression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells.Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice.RelB/p50 complexes regulate cytokine-induced YKL-40 expressionIncreasing radiosensitivity with the downregulation of cofilin-1 in U251 human glioma cells.Keeping track of the growing number of biological functions of chitin and its interaction partners in biomedical researchYKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyBreast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjectsYKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer.From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity.Genome-wide transcriptome analysis of hypothalamus in rats with inherited stress-induced arterial hypertension.YKL-40 and genetic status of CHI3L1 in a large group of asthmaticsExacerbation of experimental autoimmune encephalomyelitis in the absence of breast regression protein 39/chitinase 3-like 1.Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function.Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic DatasetsEvaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.Honokiol as a Radiosensitizing Agent for Colorectal cancers.A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma.Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII StudyFBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma.
P2860
Q24624033-80BA2209-3DEF-4617-8E72-1BB8666E5EECQ26745913-A88AF905-0B4D-4C28-BC2D-EBED4C00BF5AQ26781833-2C655AFC-3CEE-40B9-B278-BA733E3034A7Q26799885-106A9EA0-D630-4C11-8ECB-7F88E3A6968DQ26865533-D684B724-7035-4D4C-B2EF-055971503FEAQ26998561-8BA29FE4-74A3-4022-AD6A-642887F4DDF9Q27317208-B4A6A6A6-B464-465A-8D21-F1DD17980B86Q33687149-0A14350F-B9F4-4D79-A913-A5D810E6AC8FQ33690239-09D6604E-7022-43A7-8244-BB4D26BF8C9DQ33823230-CE00BE9C-C89B-406F-9C6E-9727CE617731Q34052057-A93C4A56-CE10-4309-8B42-CFC4F5733436Q34155703-1F2F00C9-6B1F-466C-AFEE-A6B43532317DQ34507263-F00AC117-675F-4DDE-A7B3-A5A6CA8A91B9Q34603589-C9A40C14-717E-4255-A83E-9B35CE8649BFQ34720622-DD28F79B-AC55-4E2E-A913-B3A33F529F99Q34806348-FA59E917-788E-4BA8-A833-2ECC4A809228Q35077055-4B321C59-9C9F-4AAA-BA5C-C88029DB71CAQ35140218-C65648DD-E603-450A-B1A9-5F5805E560D1Q35154235-E3DFE70E-C369-45EA-AF28-4F7212630DEEQ35164695-C1DC58A6-3F37-4B36-8CD8-C628B1EB7C85Q35201903-8DCF8299-DDFF-429A-A187-4873B44F002BQ35216228-F2D9EA90-E6E5-4C96-AE48-B2D9120B3AB9Q35433475-3A411146-B798-442B-B4B6-B8BE5CF6B23AQ35527112-20C576FD-45C3-4D55-8033-2FCAAD3B46E5Q35557987-222981EF-1AB8-4D38-A9EF-3D0047550FC0Q35746711-8463E07D-7CAD-487F-9D87-D74956FE1077Q35828508-30CA5853-7E3B-4D1B-AF60-60EBF42057D6Q35907627-D4C7AAF3-832F-4F6E-8C2E-9BB1EA317C1AQ36300687-2E919B3F-8E13-4075-9232-E52EC1F5504FQ36346806-6F2763C7-55B5-4093-8D5F-7B0A937B82D3Q36545468-4DB64D16-D18C-4F25-B69F-3AB012BC22A5Q36574753-E59023E0-1AF4-40FC-842A-A5BCABB822B6Q36884393-4A0C9DCE-9822-42F1-8A8C-811003218BFDQ37176425-578EE437-3CC4-40CA-BF5F-B3B4EA50AC6DQ37191560-303BBC75-A79F-4556-ADC5-95324F74B986Q37351849-7062E09E-74B6-4DB9-BA71-9A5C67F5FD13Q37514165-771A4618-B631-4C85-9317-AFF796EC3DAAQ37537572-CCB34B46-A981-4712-B313-4268C9718D2FQ37548804-1A615130-85DD-4468-B3E2-43D71E78DE17Q37596139-A49828F4-AA8E-4169-B43A-ADD60DE5A60A
P2860
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@ast
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en-gb
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@nl
type
label
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@ast
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en-gb
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@nl
prefLabel
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@ast
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en-gb
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@nl
P2093
P2860
P921
P3181
P356
P1476
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma
@en
P2093
Brooke Bentley
Luis Moral
Michael Faibish
Ralph A Francescone
Sherry L Taylor
Steve Scully
P2860
P304
P3181
P356
10.1074/JBC.M110.212514
P407
P577
2011-04-29T00:00:00Z